Visit https://www.apbioinc.com/en/ for more information about AP Biosciences and its pipeline of next- generation cancer therapies. About AP402 AP402 is a first-in-class bispecific antibody originated and developed by AP Biosciences to target p95HER2, a truncated variant of HER2 that is expressed in 30-40% of treatment-resistant HER2-positive cancers. AP402 is constructed using T-cube bispecific antibody technology which combines p95HER2 targeting with a CD137 activation domain to enable target-dependent T- ...